Business Context and Reporting Period
This Form 8-K is a current report filed by Zafgen, Inc. (noting a discrepancy with the metadata request for Larimar Therapeutics) on September 17, 2019. The filing addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance:
- Stock Price: The closing bid price of the common stock was below $1.00 per share for 30 consecutive trading days preceding September 17, 2019.
- Trading Symbol: ZFGN on the Nasdaq Global Market.
Material Changes
The material event reported is the receipt of a formal notice from Nasdaq indicating a failure to satisfy the Minimum Bid Price Requirement (Rule 5550(a)(1)). This represents a deviation from the required listing standard of maintaining a closing bid price of at least $1.00 per share.
Outlook, Risks, and Contingencies
Compliance Period: The company has been granted an 180-day compliance period ending on March 16, 2020, to regain compliance.
Path to Compliance: To maintain listing on the Nasdaq Global Market, the stock must close at or above $1.00 for a minimum of 10 consecutive business days within the compliance period.
Contingencies and Risks:
- Transfer to Capital Market: If the company fails to regain compliance by the deadline, it may transfer to The Nasdaq Capital Market, provided it meets other listing standards (such as market value of publicly held shares).
- Reverse Stock Split: The company may consider a reverse stock split to cure the deficiency if transferring to the Capital Market.
- Delisting Risk: If the company fails to regain compliance by the end of the compliance period (or any extended period), the common stock will be subject to delisting.
Investor Verification Checklist
- Verify the current closing bid price of ZFGN to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for 10 consecutive days of trading at or above $1.00 to confirm compliance.
- Review subsequent filings for announcements regarding a potential reverse stock split or transfer to the Nasdaq Capital Market.
- Confirm the company's market value of publicly held shares to ensure eligibility for the Nasdaq Capital Market if a transfer becomes necessary.